Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer
Authors:
- 11 March 2010
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 17 (6) , 805-810
Abstract
Prostate cancer is one of the most prevalent cancers in men. Replication-competent oncolytic herpes simplex virus (oHSV) vectors are a powerful antitumor therapy that can exert at least two effects: direct cytocidal activity that selectively kills cancer cells and induction of antitumor immunity. In addition, oHSV vectors can also function as a platform to deliver transgenes of interest. In these studies, we have examined the expression of a xenogeneic homologue of the prostate cancer antigen, prostatic acid phosphatase (PAP), with the goal of enhancing virotherapy against PAP-expressing tumors. PAP has already been used for cancer vaccination in patients with prostate cancer. Here we show that treatment with oHSV bPΔ6 expressing xenogeneic human PAP (hPAP) significantly reduces tumor growth and increases survival of C57/BL6 mice bearing mouse TRAMP-C2 prostate tumors, whereas expression of syngeneic mouse PAP (mPAP) from the same oHSV vector did not enhance antitumor activity. Treatment of mice bearing metastatic TRAMP-C2 lung tumors with oHSV-expressing hPAP resulted in fewer tumor nodules. To our knowledge, this is the first report of oncolytic viruses being used to express xenoantigens. These data lend support to the concept of combining oncolytic and immunogenic therapies as a way to improve therapy of metastatic prostate cancer.Keywords
This publication has 38 references indexed in Scilit:
- Prostate Stem Cell Antigen DNA Vaccination Breaks Tolerance to Self-antigen and Inhibits Prostate Cancer GrowthMolecular Therapy, 2009
- Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cellsCancer Gene Therapy, 2009
- Recurrent gene fusions in prostate cancerNature Reviews Cancer, 2008
- Current controversies in the treatment of high-risk prostate cancerCurrent Opinion in Urology, 2008
- Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16Oncogene, 2008
- Virotherapy with a Type 2 Herpes Simplex Virus–Derived Oncolytic Virus Induces Potent Antitumor Immunity against NeuroblastomaClinical Cancer Research, 2007
- Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vectorInternational Journal of Cancer, 2004
- Oncolytic herpes simplex virus vectors for cancer virotherapyCancer Gene Therapy, 2002
- Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancerInternational Journal of Cancer, 1997
- Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphataseFEBS Letters, 1988